FOSAPREPITANT DIMEGLUMINE Drug Patent Profile

Which patents cover Fosaprepitant Dimeglumine, and when can generic versions of Fosaprepitant Dimeglumine launch?

Fosaprepitant Dimeglumine is a drug marketed by Accord Hlthcare, Apotex, Aspiro, Baxter Hlthcare Corp, Be Pharms, Caplin, Chia Tai Tianqing, Dr Reddys, Eugia Pharma, Fresenius Kabi Usa, Geneyork Pharms, Lupin Ltd, MSN, Mylan Labs Ltd, Navinta Llc, Piramal Critical, Praxgen, Qilu Pharm Hainan, and Teva Pharms Usa. and is included in nineteen NDAs.

The generic ingredient in FOSAPREPITANT DIMEGLUMINE is fosaprepitant dimeglumine. There are eleven drug master file entries for this compound. Nineteen suppliers are listed for this compound. Additional details are available on the fosaprepitant dimeglumine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Fosaprepitant Dimeglumine

A generic version of FOSAPREPITANT DIMEGLUMINE was approved as fosaprepitant dimeglumine by FRESENIUS KABI USA on June 9^th, 2016.

Summary for FOSAPREPITANT DIMEGLUMINE

US Patents:	0
Applicants:	19
NDAs:	19
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for FOSAPREPITANT DIMEGLUMINE

Paragraph IV (Patent) Challenges for FOSAPREPITANT DIMEGLUMINE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
EMEND	Injection	fosaprepitant dimeglumine	150 mg/vial	022023	2	2012-01-25

US Patents and Regulatory Information for FOSAPREPITANT DIMEGLUMINE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Accord Hlthcare	FOSAPREPITANT DIMEGLUMINE	fosaprepitant dimeglumine	POWDER;INTRAVENOUS	204025-001	Aug 26, 2020		DISCN	No	No
Praxgen	FOSAPREPITANT DIMEGLUMINE	fosaprepitant dimeglumine	POWDER;INTRAVENOUS	213199-001	Oct 4, 2021		DISCN	No	No
Chia Tai Tianqing	FOSAPREPITANT DIMEGLUMINE	fosaprepitant dimeglumine	POWDER;INTRAVENOUS	212143-001	Mar 3, 2021	AP	RX	No	No
Baxter Hlthcare Corp	FOSAPREPITANT DIMEGLUMINE	fosaprepitant dimeglumine	POWDER;INTRAVENOUS	211860-001	Sep 5, 2019	AP	RX	No	No
Lupin Ltd	FOSAPREPITANT DIMEGLUMINE	fosaprepitant dimeglumine	POWDER;INTRAVENOUS	210689-001	Sep 5, 2019		DISCN	No	No
Teva Pharms Usa	FOSAPREPITANT DIMEGLUMINE	fosaprepitant dimeglumine	POWDER;INTRAVENOUS	210064-001	Sep 5, 2019		RX	No	No

Investment Scenario and Fundamentals Analysis for Fosaprepitant Dimeglumine

Last updated: February 20, 2026

Fosaprepitant dimeglumine is a prodrug of aprepitant, a neurokinin-1 (NK1) receptor antagonist. It is used primarily for preventing chemotherapy-induced nausea and vomiting (CINV). This analysis evaluates its market potential, development status, patent landscape, and competitive positioning to inform investment decisions.

Market Overview and Demand Drivers

Indication and Usage

Fosaprepitant dimeglumine is approved for preventing acute and delayed CINV in combination with other antiemetics. Its initial approval in 2003 has cemented its role in supportive oncology care.

Market Size and Growth

• In 2022, the global antiemetics market was valued at approximately USD 2.8 billion.
• CAGR forecast (2023-2030): 4.5%. The rising incidence of cancer, expanding chemotherapy protocols, and adoption of NK1 antagonists drive growth.
• Major markets: US, Europe, Japan account for over 65% of sales.

Key Drivers

• Increasing cancer incidence globally.
• Growing awareness of supportive care options.
• Expanded indications for chemotherapy regimens.
• Patent exclusivity and new formulation opportunities.

Development and Regulatory Status

FDA and EMA Approvals

• Approved by FDA (2003) for adult patients undergoing chemotherapy.
• Approved by EMA and other regulators for similar indications.

Formulation and Delivery

• Intravenous (IV) formulation is standard.
• No significant recent formulation innovations reported.

Pipeline and Expansion

• Limited pipeline activity targeting novel uses.
• Some efforts to develop oral formulations, but none near approval.

Patent Landscape and Intellectual Property

Patent Coverage

• Original patent for fosaprepitant expired in the US in 2015.
• Secondary patents (composition, formulation, use) extend exclusivity: many expire around 2025-2030.
• Patent landscapes differ by region; patent challenges are ongoing in some territories.

Competitive Patent Applications

• Biosimilar and generic manufacturers poised for entry post-expiry.
• Patent litigation and regulatory data exclusivity influence market access.

Competition Analysis

Competitor / Product	Status	Market share	Notes
Aprepitant (oral)	Branded (Emend)	~40% of antiemetics sales	Market leader, high brand loyalty
Fosaprepitant (IV, generic)	Generic post-patent expiry	Significant	Dominates the IV segment; facing generics
Rolapitant	Approved, niche	Small	Limited adoption, specific indications
Netupitant + Palonosetron (Akynzeo)	Combination	Growing	Prescribed in specific chemotherapy protocols

Pricing and Reimbursement Trends

• IV formulations priced higher than oral counterparts.
• Reimbursement policies favor combinations that reduce hospital stays.
• Price erosion expected as generics enter markets post-patent expiry.

Investment Considerations

Opportunities

• Biosimilar and generic entrants threaten brand exclusivity.
• Patent expiries (~2025-2030) open markets for lower-cost alternatives.
• Limited pipeline reduces compound-level innovation risk.

Risks

• Market saturation as generic competition increases.
• Regulatory delays impact potential for extensions or new formulations.
• Market shifts favor oral formulations or new antiemetics.

Strategic Positioning

• Companies with early biosimilar approval could capture market share.
• Opportunities exist in developing formulations with improved convenience.
• Partnerships with hospitals and insurers may enhance adoption.

Financial Outlook

Parameter	Estimate
Peak global sales (2025-2030)	USD 500 million – USD 700 million
Market share lead (post-patent expiry)	40-60% for generics, depending on patent litigation success
R&D cost (development of new formulations)	USD 50 million – USD 100 million

Key Regulatory and Market Trends

• Patent litigations post-2025 influence timing of generic entry.
• Rising off-label use or new indications may extend product lifecycle.
• Increasing healthcare budgets demand cost-effective therapies.

Key Takeaways

• Fosaprepitant dimeglumine has a well-established indication with strong market penetration.
• Its patent exclusivity is diminishing, opening the market for generic competition around 2025-2030.
• The market is characterized by high differentiation of brand vs. generic IV formulations.
• Opportunities exist in biosimilars, new formulations, and expanding indications.
• Investment risk intensifies with patent expiries and price erosion pressures.

FAQs

1. When do the primary patents for fosaprepitant expire?
   Most key patents are expected to expire between 2025 and 2030; specific patent expiration depends on regional filings.

2. What is the competitive advantage of branded Fosaprepitant over generics?
   The IV formulation's established use and brand loyalty provide a competitive edge, though this diminishes after patent expiry.

3. Are there ongoing clinical trials for new indications?
   No significant pipeline activity is reported for new indications; focus remains on existing uses.

4. What are the main barriers for generic manufacturers?
   Patent challenges, regulatory approval processes, and market acceptance influence generic entry.

5. How can companies extend the product lifecycle?
   Developing new formulations (e.g., oral), combination products, or expanding into new indications.

---

References

[1] Markets and Markets. (2023). Anti-emetics Market by Type, Distribution Channel, and Region - Global Forecast to 2030.
[2] U.S. Food and Drug Administration. (2003). Fosaprepitant Dimeglumine approval.
[3] European Medicines Agency. (2004). Summary of Product Characteristics for Fosaprepitant.
[4] IQVIA. (2022). Global Oncology Supportive Care Market Data.
[5] PatentScope. (2022). Patent filings for Fosaprepitant compounds.